Teleflex Expands QuikClot Control+™ Device Indications
Teleflex Incorporated (NYSE: TFX), a renowned leader in medical technology, has recently received approval from the U.S. Food and Drug Administration (FDA) for a significant expansion of the indications for use of its innovative QuikClot Control+™ Hemostatic Device. This advanced device is now authorized for the temporary control of all grades of internal and external bleeding, broadening its clinical applications.
User Benefits and Market Impact
Previously, the QuikClot Control+™ Device was primarily indicated for managing class III and IV internal organ space bleeding, which includes severely bleeding surgical wounds and mild to moderate bleeding during cardiac surgeries. This latest FDA clearance marks a pivotal change aimed at addressing a critical healthcare challenge: uncontrolled bleeding, a leading cause of both mortality and morbidity in patients.
Expert Insights on Bleeding Management
Kevin Robinson, President and General Manager of Anesthesia and Emergency Medicine at Teleflex, emphasized the importance of effective bleeding control in the surgical context. He noted, "Uncontrolled bleeding can have devastating impacts on patient outcomes and healthcare costs. Our enhanced indication means we can now support more diverse medical procedures where quick and effective bleeding management is vital." This expansion aims to enhance trauma care and will also extend its support to general surgery, orthopedic procedures, gynecologic surgery, and other fields, significantly affecting the healthcare landscape.
Research and Evidence Supporting the Indication Expansion
To support the revised labeling, Teleflex leveraged real-world evidence (RWE) derived from a retrospective observational study involving 603 patients across emergency and trauma settings. This comprehensive research demonstrated the QuikClot Control+™ Device's efficacy and safety in controlling various grades of bleeding across multiple anatomical sites, affirming its role as a reliable tool in surgical and emergency medicine.
Policy and Clinical Outcomes
Michelle Fox, Corporate Vice President and Chief Medical Officer at Teleflex, expressed her enthusiasm about the FDA's decision. "Real-world evidence was crucial in supporting this expanded indication, allowing us to bring advanced technology to clinicians aiming to improve bleeding control across medical settings. We believe this enhanced capability can significantly benefit both patients and healthcare providers across the board." Teleflex remains committed to enhancing patient care through innovative solutions.
Global Presence and Future Aspirations
The QuikClot Control+™ Hemostatic Device is not only approved in the United States but also holds indications in the European Union for similar applications, following its commercialization in the EU in the prior year. Teleflex's global reach amplifies the potential health innovations that can transform patient care worldwide.
About Teleflex Incorporated: Teleflex is dedicated to improving the health and quality of lives through innovative medical technologies. Our vision as a trusted partner in healthcare motivates us to offer a diverse portfolio of solutions across various therapy areas including anesthesia, interventional cardiology, emergency medicine, and surgical care.
We believe that exceptional people, purpose-driven innovation, and a commitment to quality are the cornerstones of future healthcare advancements. Teleflex's array of trusted brands, including Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™, and Weck™, exemplify our dedication to this mission.
Frequently Asked Questions
What is the QuikClot Control+™ Hemostatic Device?
The QuikClot Control+™ is a medical device designed for the temporary control of internal and external bleeding, enhancing patient safety during surgical and emergency procedures.
How does the FDA clearance affect the use of the device?
This clearance allows for the QuikClot Control+™ to be used in a wider range of clinical situations, addressing all grades of bleeding.
What types of surgeries can benefit from this device?
The device is indicated for use in general surgery, orthopedic surgery, gynecologic surgery, and trauma care.
What evidence supports the effectiveness of the QuikClot Control+™?
A recent observational study involving over 600 patients has shown that the device effectively controls various grades of bleeding in multiple anatomical locations.
How can I learn more about Teleflex products?
For more information on Teleflex and its innovative medical solutions, please visit their official website.
